Viz.ai has partnered with Alnylam Pharmaceuticals to develop an AI-based care pathway for cardiac amyloidosis.
The Viz Cardiac Amyloidosis Care Pathway is designed to accelerate early identification and standardize diagnostic evaluation of the condition, Viz.ai said.
Cardiac amyloidosis is associated with misfolded proteins deposited in the heart muscle and can lead to heart failure and poor outcomes if left untreated, the company noted.
Using AI to automatically analyze standard echocardiograms, the program will identify patients with symptoms of cardiac amyloidosis, and enable coordinated confirmatory testing, referral, and follow-up across cardiology and heart failure teams, the company explained.
The pilot program will launch with a multisite study to evaluate clinical workflow integration and generate real-world evidence on its impact on diagnosis, time to treatment, and care coordination, the company said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
